Navigation Links
Hospira Acquires Sculptor
Date:4/30/2008

- Acquisition Provides Bar Code Point-of-Care Technology to Enhance Patient

Safety and Clinician Workflow Capabilities -

LAKE FOREST, Ill., April 30 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, and St. Clair Health Corporation, today announced that Hospira has acquired Sculptor Developmental Technologies, a subsidiary of St. Clair Health Corporation. Sculptor is a leading software engineering company formed by St. Clair Hospital in 1993 to advance the use of technology to improve patient care. As part of a related arrangement, St. Clair Hospital will serve as a development and test site for Hospira medication management products.

"Acquiring Sculptor expands Hospira's ability to offer device and software solutions that enhance safety and productivity," said Chris Kolber, president, Global Devices, Hospira. "Their approach to developing products designed by clinicians, for clinicians, results in high adoption rates and an immediate impact to patient safety and clinician efficiency."

Sculptor developed VeriScan Rx, a software application that supports bar code medication administration at the point of care. It is designed to streamline the medication administration process to enhance patient safety and clinician workflow.

According to the Institute of Medicine (IOM), medication errors impact 1.5 million people in the United States per year. Bar code enabled systems are becoming increasingly important to addressing medication errors by verifying the "five rights" of medication administration: right medication, right dose, right patient, right time and right route of administration.

"This acquisition brings together two leaders in healthcare IT -- Hospira has led the industry in barcoding medications and infusion technology; and St. Clair, through Sculptor, was the first hospital in the country to combine barcoding and RFID in a single mobile device for the real-time workflow needs of clinical staff," said Richard Schaeffer, vice president and chief information officer, St. Clair Hospital.

The acquisition of Sculptor supports Hospira's approach of interfacing its products with other technologies to meet the evolving needs of hospitals. Hospira currently partners with several leading hospital information system providers to establish communications between their applications and its own. These companies include Cerner Corp., McKesson Corporation and Siemens Medical Solutions.

Financial details of the Sculptor agreement were not disclosed.

About Sculptor Developmental Technologies, Inc.

Sculptor Developmental Technologies, Inc. was established in 1993 as a software engineering company dedicated to providing software solutions for healthcare. With the advent of VeriScan in 2003, Sculptor remains focused on bedside patient safety initiatives. Currently there are more than 125 hospitals in the United States, Canada and Europe using Sculptor's applications.

About St. Clair Hospital

St. Clair Hospital is a leading acute care hospital serving the approximately 400,000 residents of the South Hills of Pittsburgh with a comprehensive array of inpatient and outpatient services. The Hospital regularly receives state and national recognition for clinical excellence, patient safety, and information technology, including the 2007 Leadership Award for Clinical Excellence from VHA, and distinction as a best practice facility from the Institute for Healthcare Improvement (IHI) for medication reconciliation. St. Clair is among Pennsylvania's highest achieving hospitals in patient safety initiatives and clinical best practices, and is the only Pittsburgh-area hospital to be named one of the 100 Best Places to Work in Pennsylvania for six consecutive years.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com.
Private Securities Litigation Reform Act of 1995 -- A Caution Concerning

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks and uncertainties set forth under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which is incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
2. Hospira to Present at the Bear Stearns 10th Annual London Healthcare Conference on March 13
3. Hospira Reports Fourth-Quarter and Full-Year 2007 Results
4. Hospira Launches Generic Irinotecan Injection
5. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
6. Hospira Hosts Conference Call for Fourth-Quarter 2007 Results and 2008 Projections
7. Hospira to Present at the JPMorgan 26th Annual Healthcare Conference on January 9
8. Hospira Reports Third-Quarter 2007 Results
9. Hospira to Present at the Credit Suisse Phoenix Health Care Conference on November 13
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... 24, 2016 , ... The number of health insurance policies ... over last year, according to data in the forthcoming AIS’s Directory of Health ... with a slight decrease in risk-based groups and a slight increase in administrative-services-only/self-funded ...
(Date:5/24/2016)... ... May 24, 2016 , ... Bio-Logic Aqua® Research Water Life ... and a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss healthier lifestyles, ... 16, 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated to her ...
(Date:5/24/2016)... ... ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene Day on May 28 and ... who do not have access to a toilet, even when they’re on their periods. , ... The (sometimes hilarious) results help shine a light on the awkwardness that women face while ...
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent ... of the potential of contaminated well water throughout the Houston area. , Heavy floodwaters ... well water that’s exposed to contaminants. Residents may not even be aware of the ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... today announced a licensing relationship that will deliver a new series of Q&A ... will put the medical knowledge and expertise of Harvard Medical School faculty into ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
(Date:5/24/2016)... KONG , May 24, 2016 /PRNewswire/ ... COMBO ™ , la première ... des cathéters destinés à l,intervention portant sur ... (FAV)   OrbusNeich, entreprise mondiale ... permettant de changer la vie, a élargi ...
Breaking Medicine Technology: